Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cefuroxime + triamcinolone acetonide
- Development stage
- Unknown
- Lead developer
- University of California, San Francisco
- Modality
- Small Molecules
- Administration
- Intracameral, Subconjunctival
01
Overview
The Dropless Regimen developed by the University of California, San Francisco is a postoperative treatment protocol for cataract surgery designed to replace traditional multi-drop eye regimens. It consists of a combination of two small molecule drugs: cefuroxime, a second-generation cephalosporin antibiotic, and triamcinolone acetonide, a synthetic corticosteroid. Cefuroxime is administered via intracameral injection to prevent endophthalmitis by inhibiting bacterial cell wall synthesis, while triamcinolone acetonide is delivered via subconjunctival injection to provide sustained anti-inflammatory effects. This approach is specifically being evaluated in safety-net hospital populations to improve treatment adherence and reduce the burden of complex postoperative care.
- Other names
- Dropless RegimenDropless Postoperative Regimen
02
Targets
PBP (Penicillin-binding protein family)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on cefuroxime + triamcinolone acetonide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cefuroxime + triamcinolone acetonide.